XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.4
Basis of Presentation and Summary of Significant Accounting Policies - Summary of Segment Reconciliation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development $ 35,329 $ 36,852
Total selling, general and administrative 14,224 12,482
Salaries and staff costs    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 7,131 6,903
Total selling, general and administrative 3,973 3,286
Stock-based compensation    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 2,376 1,660
Total selling, general and administrative 3,317 3,100
Clinical trials, outside services, and lab supplies    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 23,954 26,472
Outside services and professional fees    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total selling, general and administrative 5,262 4,369
Facilities and other    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total research and development 1,868 1,817
Total selling, general and administrative $ 1,672 $ 1,727